For the multinational pharmaceutical company Menarini, the years of the pandemic coincided with a strong growth in turnover. In 2022, the Aleotti family group achieved a turnover of €4.154 billion, up 6% compared to 2021. These numbers are the new post-pandemic starting point of the increasingly global development of the largest pharmaceutical company with Italian capital. Already today, in the breakdown of consolidated turnover, we see a strong international exposure, with 22% of the turnover achieved in Italy and 78% internationally. Growth expectations today largely concern the United States, especially after developments on the latest market operations and the results obtained through oncology research. Lucia Aleotti, shareholder and board member of the group, explained to Il Sole 24 Ore paper that "the growth of the group is directed in a timely manner towards our areas of excellence which are the area of cardiology, metabolic cardio, but also oncology, which accompanies us thanks to the development of an anticancer drug for metastatic breast cancer. We are extremely confident in 2023 and are pleased with our philosophy of investing both in research and development and in the acquisition of companies internationally, which now allows us to land in the United States.” This is an important leap because “the United States is the largest country in terms of pharmaceutical innovation. Also thanks to what analysts say about our drug, which is now considered a blockbuster, or a drug that can exceed one billion euros in sales per year, we are quite optimistic about the growth of the coming years".